98%
921
2 minutes
20
Objectives: Real-world evidence (RWE) generation can be enhanced by including patient-reported outcomes (PROs). Methods for collecting and using PRO data in the real-world setting are currently underdeveloped and there is no international guidance specific to its use in this context. This study explored stakeholders' perspectives and needs for using PROs in RWE generation. Barriers, facilitators, and opportunities for wider use of PROs in real-world studies were also investigated.
Methods: Online semi-structured interviews were conducted with international stakeholders: patients, patient advocates, regulators, payers, clinicians, academic researchers, and industry experts. Interviews were recorded, transcribed verbatim and analysed using NVivo 20. Thematic analysis was conducted based on the updated Consolidated Framework for Implementation Research (CFIR).
Results: Twenty-three interviews were conducted. Participants confirmed that the use of PROs in RWE generation is not yet well established. Participants expressed a mixed level of confidence in the value of PROs collected in a real-world setting. Operational challenges associated with collecting routine PRO data to inform care delivery at the individual level (e.g., setting up infrastructure) need to be addressed. Methodological and other challenges (e.g., financing research) associated with collecting prospective data in a real-world setting should be considered to facilitate PRO utilisation in real-world studies.
Conclusions: Several opportunities and challenges were identified regarding the broader use of PROs in RWE research. Joint efforts from different stakeholders are needed to maximise PRO implementation, with consideration given to each stakeholders' specific needs (e.g., by developing good practices).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559915 | PMC |
http://dx.doi.org/10.1016/j.heliyon.2023.e20157 | DOI Listing |
Pharmacoepidemiol Drug Saf
September 2025
IQVIA, Real World Solutions, Durham, North Carolina, USA.
Background: The quality of real-world data (RWD) directly impacts the value of real-world evidence (RWE) generated for regulatory decision-making. Data owners and investigators must be prepared to provide documentation on data quality assessments to regulators when submitting secondary data for regulatory purposes. While robust feasibility is required to justify the relevance of a data source for a specific research question, the reliability of the data, including the chain of custody and data journey prior to reaching the end user, is of equal importance for drawing valid, meaningful conclusions.
View Article and Find Full Text PDFPain
September 2025
Department of Anesthesiology, Critical Care & Pain Management, Pain Prevention Research Center at Hospital for Special Surgery, New York, NY, United States.
Real-world data (RWD) can be defined as routinely collected clinical or administrative data that might be used for research purposes and to generate real-world evidence (RWE). Computerized search and data mining methods, large electronic databases, and the development of novel computational and statistical methods allow for improved access to and analysis of RWD. Although RWD afford the opportunity to generate RWE with potentially improved efficiency and generalizability over prospective clinical studies, it is important to understand and apply best practices when analysing RWD, particularly when the goal is to generate RWE of diagnostic, prognostic, or treatment effectiveness.
View Article and Find Full Text PDFFuture Oncol
September 2025
Department of Medicine, Division of Hematology/Oncology, University of Pittsburg Medical Center, PA, USA.
Real-world evidence (RWE) is increasingly used to support product approvals and label expansions, as well as clinical and payer decision-making. Various tools (e.g.
View Article and Find Full Text PDFEur J Cancer
August 2025
Else Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden 01307, Germany; Department of Medicine I, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology
Real-world evidence (RWE), derived from real-world health data (RWD) generated during routine clinical practice, is increasingly recognized as a valuable complement to traditional clinical trial data in medical oncology. While randomized controlled trials remain the gold standard for evidence-based medicine, they often face limitations due to rising costs, ethical constraints, and the inability to cover all treatment combinations and diverse patient populations. The current impact of RWE is limited by several challenges, including data inconsistency, quality issues, and burdensome data collection processes.
View Article and Find Full Text PDFJ Pharm Pharm Sci
August 2025
Consultant, Toronto, ON, Canada.
Introduction: Patient Support Programs (PSPs) are growing globally to support early reimbursement, disease and medication dosing management. In Canada, the lack of public health support has promoted the rapid expansion of company-supported disease-specific or drug-product-specific PSPs. Data collected from these programs generate unique Canadian data serving as a valuable source of real-world data (RWD), generally adopted in EU and US as a source of evidence generation.
View Article and Find Full Text PDF